Empowering Care,
One Heart at a Time

Elucid is a medical technology company that develops AI to see invisible features of cardiovascular risk.

The company is dedicated to developing a clinical platform to help physicians deliver CCTA-guided personalized care by providing a more precise view of atherosclerosis, the root cause of cardiovascular disease.

Our Mission Statement

Elucid’s mission is to predict and personalize the prevention of heart attacks and strokes.

At Elucid, we focus on enabling efficient and transparent clinical insights to help usher in the next generation of CCTA-guided, personalized coronary artery disease care. We develop AI tools to see invisible features of risk and guide personalized, precise treatment based on a detailed analysis of patients’ atherosclerotic disease. Elucid’s platform transforms CT images into a dynamic, interactive map of disease, providing a more precise view of atherosclerosis – the root cause of cardiovascular disease – to help physicians personalize care based on a patient’s individual anatomy.

A smiling couple walks arm-in-arm through a vibrant outdoor market full of fresh vegetables and flowers.

Elucid Leadership

Andrew Miller Chief Technology Officer & SVP, Engineering

Andrew Miller

Chief Technology Officer & SVP, Engineering
Windi Hary Chief Regulatory & Quality Officer

Windi Hary

Chief Regulatory & Quality Officer
Amy Kruglak SVP, People & Leadership Development

Amy Kruglak

SVP, People & Leadership Development
Amir Ahmadi, MD Lead Scientific Advisor

Amir Ahmadi, MD

Lead Scientific Advisor

News, Media & Thought Leadership

Stay informed with the latest updates, insights, and conversations from Elucid.
Type

Elucid Announces Fifth Medicare Administrative Contractor to Cover AI Coronary Plaque Analysis

Elucid has announced that Noridian will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQTM image analysis software, beginning December 8, 2024.

Elucid Announces Favorable Medicare Coverage of AI Coronary Plaque Analysis

Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQTM image analysis software, beginning November 24, 2024.

Elucid Receives U.S. 510(k) Clearance of PlaqueIQ™ Image Analysis Software to Aid Cardiovascular Disease Assessment

Elucid has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PlaqueIQ™ imaging analysis software to help physicians diagnose cardiovascular disease (CVD).
Kelly Huang, PhD

Elucid Names Kelly Huang as CEO

Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular disease, has named Kelly Huang, PhD, as president and chief executive officer (CEO).

Elucid Commences International PRE-VUE CCT Registry Study

Elucid has initiated site recruitment for its Plaque as a Risk Factor for Evaluation of Vascular Events (PRE-VUE) CT Registry Study.
Curved modern building with many windows, set against a clear blue sky with a small white cloud.

Where to Find Us: Upcoming Events

Washington Hilton – Washington, DC – March 7-10, 2026

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Stay in Touch

Subscribe to our newsletter for the latest clinical, product and regulatory updates.

Eight people in an office sit and stand together, smiling and making heart shapes with their hands.